Brief: Quantum Genomics Completes Enrollment In Its Pharmacokinetic Clinical Study Of Firibastat
25/02/2019 17:04
Feb 25 (Reuters) - QUANTUM GENOMICS SA ALQGC.PA :
* QUANTUM GENOMICS COMPLETES ENROLLMENT IN ITS
PHARMACOKINETIC
CLINICAL STUDY OF FIRIBASTAT
* STUDY ENROLLED TWELVE HEALTHY SUBJECTS AND RESULTS OF THIS
STUDY
WILL BE AVAILABLE IN Q2 OF 2019
Source text for Eikon: ID:nGNX99fpPr
Further company coverage: ALQGC.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study